Literature DB >> 16088166

Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation of human herpesvirus 7.

Hiroyuki Hara1, Maiko Kobayashi, Ai Yokoyama, Mizuki Tochigi, Akie Matsunaga, Hidenao Shimizu, Junko Goshima, Hiroyuki Suzuki.   

Abstract

We report a 63-year-old Japanese man with epilepsy who developed skin eruptions, liver dysfunction, high fever, leukocytosis and atypical lymphocytosis 4 weeks after he had started taking carbamazepine. Titers of human herpesvirus 7 (HHV-7)-specific IgG antibodies were significantly increased and HHV-7 DNA was detected in his serum by polymerase chain reaction. These findings suggested that reactivation of HHV-7 could contribute to the development of drug-induced hypersensitivity syndrome. (c) 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088166     DOI: 10.1159/000086449

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculosis drugs and associated with human herpes virus-7 (HHV-7).

Authors:  Nehal Draz; Sumona Datta; Daniel P Webster; Ian Cropley
Journal:  BMJ Case Rep       Date:  2013-07-31

Review 2.  Characterizing DRESS syndrome recurrence: a systematic review.

Authors:  Ajay N Sharma; Samantha Shwe; Vignesh Ravi; Melanie Miller; Natasha A Mesinkovska; Nathan W Rojek; Scott Worswick
Journal:  Arch Dermatol Res       Date:  2021-09-10       Impact factor: 3.033

Review 3.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Anticonvulsant hypersensitivity syndrome associated with Epstein-Barr virus reactivation.

Authors:  Jae Yong Chang; Soo-Chan Kim
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.